Introduction
Relevance of immune cell infiltration in head and neck cancer
Immune escape mechanisms in head and neck cancer
Immune checkpoints
Clinical immunotherapy data
Clinical trial title | Phase | Target | Population |
---|---|---|---|
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040) | III | PD-1 | R/M HNSCC after platinum failure |
A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475 048/KEYNOTE-048) | III | PD-1 | R/M HNSCC first line |
Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC (PembroRad) | II | PD-1 plus Radiation | Locally advanced HNSCC |
Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232) | I | PD-1 plus oncolytic virus | R/M HNSCC after platinum failure |
Trial of Nivolumab vs Therapy of Investigator’s Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) | III | PD-1 | R/M HNSCC after platinum failure |
Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (CheckMate 651) | II | PD-1/CTLA-4 | R/M HNSCC first line |
Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | I | PD-1/LAG-3 | R/M HNSCC immunotherapy naive |
Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer | III | PDL-1/CTLA-4 | R/M HNSCC after platinum failure |